Clinical Trials Directory

Trials / Completed

CompletedNCT00805454

Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712

A Phase I, Open-Label,Positron Emission Tomography (PET) Study Healthy Subjects Following a Single Oral Dose of OPC-34712

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
15 (actual)
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

Determine the degree of striatal D2 receptor occupancy induced by OPC-34712 at differenht dose levels in healthy volunteers.

Detailed description

Subjects will receive a dose of study medication and will undergo a PET scan at 4 hrs and 23.5 hours post dose. Subjects will remain in the clinic from Day-1 to Day 7 for PK sample collection and safety monitoring. Subjects will return to the clinic on Day 10 for a follow-up safety assessment.

Conditions

Interventions

TypeNameDescription
DRUGOPC-34712Single oral dose, 0.5 to 25 mg

Timeline

Start date
2008-12-01
Primary completion
2009-07-01
Completion
2009-07-01
First posted
2008-12-09
Last updated
2010-05-07

Source: ClinicalTrials.gov record NCT00805454. Inclusion in this directory is not an endorsement.